for the Alzheimer’s Disease Neuroimaging Initiative

Metabolic syndrome · Alzheimer pathology · Mild cognitive impairment · Vascular pathology Background/Aims: This study examines the longitudinal effect of metabolic syndrome (MetS) on brain-aging indices among cognitively normal (CN) and amnestic mild cognitive impair-ment (aMCI) groups [single-domain aMCI (saMCI) and multiple-domain aMCI (maMCI)]. Methods: The study population included 739 participants (CN = 226, saMCI = 275, and maMCI = 238) from the Alzheimer’s Disease Neuroimaging Initiative, a clinic-based, multi-center prospective cohort. Confirmatory factor analysis was employed to determine a MetS latent composite score using baseline data of vascular risk factors. We examined the changes of two Alzheimer’s disease (AD) biomarkers, namely [ 18 F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) regions of interest and medial temporal lobe volume over 5 years